Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease
Status:
Recruiting
Trial end date:
2023-11-29
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics,
pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with
Cushing's disease.